BioAro Launches AI-Assisted LONgevity+™ Bioactives in U.S. and U.K
News related to:BioAro Inc · 2 min read
NEW YORK and LONDON, Sept. 23, 2026 /CourierPR/ -- BioAro Inc., a global precision-health and biotechnology company, has launched its AI-assisted LONgevity+™ bioactives in the United States and United Kingdom, following the initial launch in Dubai. The company's goal is to explore more targeted approaches to healthy aging, longevity, and healthspan through a combination of biotechnology research, scientific literature, biological pathway analysis, formulation science, and artificial intelligence.
Founded by Dr. Anmol S. Kapoor, BioAro aims to develop longevity bioactives in a more intelligent way by using what is known about biology, combined with AI and modern research tools. The LONgevity+™ portfolio was born from personal experiences, as several of the formulations were developed by Dr. Kapoor for his own use after finding that many commercially available products did not meet the level of formulation and scientific rigor he was seeking.
BioAro's approach involves evaluating how compounds may relate to biological pathways and how combinations can be formulated around specific objectives associated with healthy aging, longevity, and healthspan. The company uses AI-assisted research within its consumer-health development process to examine scientific literature, biological pathways, molecular relationships, and formulation possibilities. This helps researchers navigate a rapidly expanding body of scientific information and identify relationships that warrant further investigation.
Dr. Kapoor emphasized that AI does not replace the scientist or the physician but gives them the ability to look across an enormous amount of information and ask better questions. The science still has to make sense, he noted. BioAro's LONgevity+™ portfolio reflects the interconnected nature of longevity science, as aging involves multiple biological processes, including cellular energy, metabolic regulation, oxidative stress, inflammation, and other mechanisms.
Alongside its longevity portfolio, BioAro has developed specialized formulations for daily wellness, cognition, energy, physical performance, and recovery through its CREAGEN™ series, including CREAGEN™ Brain Boost, CREAGEN™ Raw Power, CREAGEN™ Pro Power, and CREAGEN™ Femme Energy. The range extends BioAro's formulation approach across different wellness and performance goals.
BioAro Drugs also features BioAro Intelligence, one of the company's flagship AI-assisted consumer experiences, powered by Xevyo AI. BioAro Intelligence is designed to help users begin with a health or wellness goal and explore relevant protocols, structured combinations of products, formulas, ingredients, and supporting scientific context organized around that objective.
The company's broader ecosystem spans precision health, genomics, multi-omics, microbiome science, diagnostics, artificial intelligence, drug discovery and development, and longevity. The expansion into the United States and United Kingdom follows BioAro's initial launch in Dubai and brings its LONgevity+™ portfolio into two major global consumer-health markets.
BioAro plans to expand BioAro Drugs beyond its current bioactive portfolio to include peptide-based products, pharmaceutical offerings, and online consultations, subject to applicable regulatory requirements, creating a broader platform connecting consumers with longevity products, scientific information, and professional healthcare services. The company expects to work with physicians, researchers, biotechnology companies, pharmaceutical organizations, manufacturers, and other strategic partners as the platform develops.
The launch represents a broader effort by BioAro to connect the rapidly developing fields of AI, biotechnology, precision health, and longevity within an integrated health ecosystem. Through its laboratory and technology platforms, BioAro is working to connect information from the genome, microbiome, biomarkers, and other biological systems to develop a more integrated understanding of individual biology.